Type:Injection
Generic Name:Somatropin
Manufacturer:Novartis (Bangladesh) Ltd.
Price:৳9090.29
Growth hormone deficiency, HIV-associated wasting or cachexia, Short bowel syndrome
Growth Hormone Deficiency Weight-based dosing Not to exceed 0.004 mg/kg/day SC initially for 6 weeks; may increase up to 0.016 mg/kg/day maximum Nonweight-based dosing 0.2 mg/day (0.15-0.3 mg/day range) SC initially; may increase every 1-2 months by 0.1-0.2 mg/day based on clinical response and/or serum IGF-I levels Short-bowel Syndrome 0.1 mg/kg/day SC (rotating injection sites to avoid lipodystrophy) for 4 weeks; may increase up to 8 mg/day maximum; treatment exceeding 4 weeks not studied HIV-associated Wasting or Cachexia 0.1 mg/kg/day SC at bedtime (rotating injection sites to avoid lipodystrophy) up to 6 mg/day; Alternatively: >55 kg: 6 mg/day SC 45-55 kg: 5 mg/day SC 35-45 kg: 4 mg/day SC <35 kg: 0.1 mg/kg/day SC Elderly: Lower doses may be required.
Growth Hormone Deficiency 0.024-0.034 mg/kg/day SC 6-7 days/week Small for Gestational Age Not to exceed 0.067 mg/kg/day SC Nooman Syndrome With Growth Hormone Deficiency Not to exceed 0.066 mg/kg/week SC Turner Syndrome With Growth Hormone Deficiency Not to exceed 0.067 mg/kg/day SC
Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment.
Somatropin is a synthetic human growth hormone of recombinant DNA origin. It stimulates skeletal and soft tissue growth by promoting cell division, amino acid uptake and protein synthesis. It also possesses both insulin-like and diabetogenic effects.
Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis.
Hypothyroidism, peripheral oedema; headache; muscle and joint pain; benign intracranial hypertension. Loss of glycaemic control in diabetics, New onset type 2 diabetes mellitus, Scoliosis,Hypoglycemia,Seizures,Pancreatitis,Exacerbation of psoriasis,Hematuria,Hematoma,Leukemia,Papilledema, Arthralgia,Hyperlipidemia,Otitis media,Ear disorders,Respiratory Illness,Urinary tract infection.
High doses of corticosteroid may inhibit growth-promoting effects of somatropin.
